Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

Wellstat Therapeutics given FDA nod for XURIDEN in Rare Disease

Wellstat Therapeutics Corporation has announced in September that the US Food and Drug Administration granted marketing approval for XURIDEN™ (uridine triacetate), a pyrimidine analog for uridine replacement indicated for the treatment of hereditary orotic aciduria (HOA). With the approval of XURIDEN for the treatment of HOA, the FDA also granted Wellstat Therapeutics a Rare Pediatric Disease Priority Review Voucher. HOA is an extremely rare, potentially life-threatening, genetic disorder in which patients cannot synthesize adequate amounts of uridine and consequently can suffer from hematologic abnormalities, failure to thrive, a range of developmental delays, and episodes of crystalluria leading to obstructive uropathy.

Read the full article…

Posted in Orphan Drugs and Rare Diseases | Tagged , , , , , , , , | Leave a comment

Psoriasis drug dropped by Amgen goes to Valeant

Valeant Pharmaceuticals is a very aggressive acquirer of companies and assets. The Canadian company has most recently purchased the rights to an asset from AstraZeneca in the area of psoriasis. The drug, brodalumab, was previously partnered with Amgen but the company exited the agreement from AstraZeneca earlier this year upon concerns of suicidal thoughts in patients enrolled in trials, allowing AZ to find a new partner for the late-stage asset.  

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Biotech M&A Continues to Climb the Curve

The trajectory of biotech M&A has been steep in 2015, so the $7.2bn acquisition of Receptos by oncology powerhouse Celgene, increases the gradient even further. This deal came out of left field, especially as commentators were still raking over the sizable partnering deal Celgene has just cemented with Juno Therapeutics in immuno-oncology.

Read the full article…

Posted in M&A Finance and Funding, Uncategorized | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Merck announces collaboration with Advaxis

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , | Leave a comment

UK Government names biotech veteran Minister for Life Sciences

Authored by James Sheppard

Read the full article…

Posted in Executive Appointments, M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , | Leave a comment

13 Life Science Leaders to watch in 2013 – The Verdict!

Authored by Liftstream

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Mr Pascal Soriot – AstraZeneca – Executive Leadership Series

Authored by James Sheppard

Read the full article…

Posted in Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment

ADC Therapeutics executives on fast track with funding and partners

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

CFO appointments no longer just a numbers game

Authored by Karl Simpson

Read the full article…

Posted in General, Pharmaceutical business, Recruitment Market | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Roche Returns to Antibiotics with Polyphor Deal

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap